Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

Spectra- BREAST Multimodal Hypersprectal Imaging and Raman Spectroscopy for Intraoperative Assessment of Breast Tumor Resection Margins

Coordinator
Istituti Clinici Scientifici Maugeri Societa' per Azioni Societa' Benefit, Italy
Runs
1 December 2024 to 30 November 2028
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
6 organisations in 3 countries
Type
European Innovation Council
Grant agreement
101187508

What the project is doing

In the project's own words, from its summary on CORDIS.

The Spectra-BREAST project aims to revolutionize the assessment of tumor resection margins during breast conserving surgery (BCS). Currently, approximately 20% of breast cancer patients require a second operation due to incomplete removal of cancerous tissue. This results in increased costs for the healthcare system and significant negative effects on patients’ well-being. Nowadays, the standard margin assessment procedure is postoperative histopathological specimen analysis, which takes several days to complete.

Although intraoperative histopathological analysis on frozen tissue is possible, it is less effective and cannot be implemented in all clinical centers. Alternative techniques have been suggested but have low diagnostic performance or take excessive time to assess the entire resected specimen. Spectra-BREAST aims to support surgeons with an intraoperative tool providing accurate and actionable feedback on the resection margin status over the whole specimen in less than 5 minutes.

To this end, we will apply a radically new, high-risk multimodal approach combining two optical techniques, Hyperspectral Imaging (HSI) and fiber-optic Raman Spectroscopy (RS) with AI-based data-analysis. HSI and AI will be used for fast and sensitive detection of suspicious margins, which are subsequently analyzed by RS, and a second AI will make the final prediction on the RS spectra. The ambition is to identify tumors on and below the resection surface (up to a depth of 2 mm), with an unprecedented high sensitivity and specificity (over 95%) in real-time.

Spectra-BREAST also has the potential for wider applications, going beyond breast cancer to include margin assessment for other cancers, robotic/laparoscopic surgery, and guided biopsy. Finally, Spectra-BREAST will offer an objective technology reducing variability between patients, and most importantly, will improve patient outcomes such as reduced hospital stays, complications, anxiety, and improved cosmetic outcomes.

Topics

Who is involved

OrganisationCityCountryRole
Istituti Clinici Scientifici Maugeri Societa' per Azioni Societa' BenefitPaviaItalyCoordinator
Universidad Politecnica De MadridMadridSpainParticipant
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Nireos SRLMilanoItalyParticipant
Politecnico Di MilanoMilanoItalyThird party
Riverd International BVRotterdamNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI